Immunotherapy for HNSCC
Panelists Ezra Cohen, MD; Barbara A. Burtness, MD; Jared Weiss, MD; and Joshua M. Bauml, MD, discuss the use of pembrolizumab in patients with head and neck squamous cell carcinoma and how the FDA approval for pembrolizumab is not reliant on PD-L1 status.
